WO2005014610A1 - 酸化により機能性ユニットを放出するヌクレオシドおよびそれを含むオリゴヌクレオチドの製造法 - Google Patents
酸化により機能性ユニットを放出するヌクレオシドおよびそれを含むオリゴヌクレオチドの製造法 Download PDFInfo
- Publication number
- WO2005014610A1 WO2005014610A1 PCT/JP2004/011039 JP2004011039W WO2005014610A1 WO 2005014610 A1 WO2005014610 A1 WO 2005014610A1 JP 2004011039 W JP2004011039 W JP 2004011039W WO 2005014610 A1 WO2005014610 A1 WO 2005014610A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotide
- group
- nucleotide
- shows
- oxidation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6823—Release of bound markers
Definitions
- the present invention provides a functional unit and a reporter unit which are bonded to a base moiety by oxidation.
- DNA biosensors have provided a convenient and fast method for extracting necessary information from target genes.
- various DNA probe forces such as a DNA probe that gives a sequence-specific signal such as a molecular beacon have been used for this purpose (see Non-Patent Documents 11 to 13).
- a DNA probe that gives a sequence-specific signal such as a molecular beacon
- there were few DNA probes capable of releasing useful functional molecules see Non-Patent Documents 416).
- Non-patent literature l Tyagi, S., et al "Nat. Biotechnol., 1996, 14, 303-308
- Non-Patent Document 2 Tyagi, S., et al "Nat. Biotechnol., 1998, 16, 49-53
- Non-Patent Document 3 Piatek, A.S., et al., Nat. Biotechnol., 1998, 16, 359-363.
- Non-patent document 4 Ma, Z., et al., Pro Natl. Acad. Sci. USA, 2000, 97, 11159-11163
- Non-patent document 5 Ma, Z., et al., Med. Chem., 2001 , 9, 2501-2510
- Non-patent Document 6 01-1110 0, Eighth, et al., Angew. Chem. Int. Ed., 2003, 42, 2502-2504
- a system that can release specific molecules by external stimuli such as oxidation or light irradiation is a very useful technique for gene analysis and treatment and diagnosis of various diseases.
- the present invention makes it possible to easily release a useful substance such as a dye or drug bound to an oligonucleotide without damaging a target nucleic acid, and to introduce the substance into a target moiety by the release.
- a possible method and a novel base therefor are provided.
- a functional unit can be released from a nucleic acid by an external stimulus such as light irradiation or treatment with an oxidizing agent. Therefore, it becomes possible to release a drug 'reporter molecule at a specific nucleic acid sequence and to attach and detach a label on a nucleic acid, that is, the following can be expected.
- the present inventors have designed drug-releasing nucleosides based on the mechanism by which guanine is degraded by the generation of holes.
- X and Y each independently represent _ ⁇ —NH— -N (alkyl) —S—, R represents a functional unit, a reporter unit, or a biofunctional molecule; R 2 each independently represents a hydrogen atom, a phosphate bonding group, a phosphoramidite group, or a nucleotide, and n represents a number from 1 to 10.
- nucleotide or an oligonucleotide containing the same can be used as a nucleotide or an oligonucleotide containing the same.
- the present invention also relates to a method for releasing an R group in the base using an oligonucleotide containing the nucleotide of the present invention.
- the present inventors produced a guanine derivative in which position 8 of guanine was substituted with a hetero atom.
- Ethylenediamine was employed as a group having a heteroatom to be introduced at the 8-position.
- the production example is shown below.
- a compound (1) in which the 5'-position of 8-glomoguanine is protected with a 4,4'-dimethoxytrityl (DMTr) group is treated with ethylenediamine to obtain a guanine derivative (2) having an ethylenediamino group introduced at the 8-position.
- DMTr 4,4'-dimethoxytrityl
- the cyano phosphoramidide method (for example, compound (5))
- eda G A guanine derivative having an ethylenediamino group at the 8-position (hereinafter abbreviated as eda G) by removing the protecting groups at the 8-terminal amino group and the 2-amino group as an oligonucleotide by binding to another nucleotide. .) it was oligonucleotides (6) by introducing a variety of molecules Amino group at the end of the modified Guanin derivatives in this Echirenjiamin it could obtain the N- modified one eda G containing.
- the above reaction formula shows an oligonucleotide (7) modified with an R—CO— acidol group.
- oligonucleotides (6) Sukushi benzoate ',,; ⁇ and Ding _ scan thousand, and ⁇ , Seo, by teeth of, can be obtained Benzoiru _ eda G.
- the present inventors have proposed an oligonucleotide (7) containing G ⁇ ea G), for example, 5, _d (TATAAT GTAATAT) _3 ,:
- Figure 1 shows the results of HPLC of this single-stranded oligonucleotide (ODN) by oxidation.
- Figure 1 (a) shows the HPLC of the single-stranded oligonucleotide (ODN) as the raw material, and
- Figure 1 (b) shows the HPLC.
- 4 shows the results of HPLC of the decomposition products by light irradiation.
- FIG. 1 (c) shows the results of HPLC of decomposition products of oxidation by iridium described below.
- FIG. 2 shows the results of MALDI-TOF of decomposition products by light irradiation.
- the peak at 2370.61 in FIG. 2 is the peak of the starting oligonucleotide used as the internal standard.
- the peak at 19 67.68 indicates the decomposition product on the 5 ′ side (8), and the peak at 1870.11 indicates the decomposition product on the 3 ′ side (9).
- FIG. 3 shows the results of LC-ESI / MSZMS analysis of a single-stranded oligonucleotide (ODN) irradiated with light.
- ODN single-stranded oligonucleotide
- the upper part of Fig. 3 shows the eluate containing MS207, the middle part shows the fragmentation of MS207, and the lower part shows the liquid chromatography using an Intac C-18 column (2. OX 50mm). This shows the elution pattern of.
- the oxidation potential (E) of this Bz eda G was 0.59 V (VS NHE). This oxidation potential,
- TAMRA tetramethylrhodamine
- X represents tetramethylrhodamine (TAMRA) -eda G.
- TAMRA tetramethylrhodamine
- this oligonucleotide is referred to as “ ⁇ DN2 (T)”), and a cyanobenzophenone mono-modified peridine (U *) for injecting holes was introduced instead of the seventh thymine (T).
- T seventh thymine
- the photolysate from the oligonucleotide was separated by a centrifugal filter (micron YM-3) and the fluorescence at 576 nm was measured. Strong fluorescence could be measured from the filtrate of ⁇ DNlZ ⁇ DN2 (U *).
- the filtrate of ⁇ DNlZ ⁇ DN2 (U *) showed about 7 times the fluorescence of the filtrate of the control ODN1 / ODN2 (T). The results are shown in FIG. In (A) of FIG.
- a black circle (hata) indicates the case of ODN1 / ODN2 (U *), and a black square (country) indicates the case of ⁇ DN lZ ⁇ DN2 (T).
- the vertical axis of (A) in FIG. 5 shows the fluorescence intensity (a.u.), and the horizontal axis shows the time (minutes) from light irradiation.
- FIG. 6 shows the change in the fluorescence intensity as a result of irradiating the double-stranded DNA ⁇ DN1 / ⁇ DN2 (U *) with light at 312 nm.
- the vertical axis in FIG. 6 shows the fluorescence intensity (au), and the horizontal axis shows the wavelength (nm).
- FIG. 7 shows the results of PAGE analysis of the degradation products when the double-stranded DNA ⁇ DN1 / ⁇ DN2 (U *) was irradiated with light at 312 nm.
- the ⁇ DN after light irradiation was heat-treated at 50 ° C. for 20 minutes in 50 ⁇ L of 10% piperidine (V / v).
- X in FIG. 7 indicates TAMRA- eda G.
- Lane 1 in Fig. 7 shows the case of the G + A sequence by the Maxam-Gilbert method
- lane 2 shows the full-length ODN 1
- lane 3 shows the one immediately after light irradiation
- lane 4 shows the one after light irradiation for 30 minutes.
- lane 5 shows the result of light irradiation for 60 minutes.
- FIG. 8 The fluorescence of the sample irradiated with light can also be confirmed visually.
- the result is shown in FIG.
- the left side of FIG. 8 is for the sample from ⁇ DNl / ODN2 (T), and the right side is for the sample with ⁇ DNlZ ⁇ DN2 (U *) force.
- Most of the fluorescence was observed in the sample with ⁇ DNlZ ⁇ DN2 (T) force on the left side of Fig. 8 could not.
- the guanine derivative of the present invention having a molecule in which the 8-position is bonded by a hetero atom releases the bonded molecular species by oxidation, that is, electron donation.
- the present invention provides such a guanine derivative and an oligonucleotide containing the same.
- the release of the molecular species in the guanine derivative of the present invention is induced by relatively mild oxidation, and the release of such molecular species is not limited to the analysis of the gene by the release of the fluorescent tag but a specific site in the living body. Thus, it is extremely useful as a vector for releasing drugs.
- the guanine derivative of the present invention having a molecule in which the 8-position is bonded by a hetero atom has a structure of a released molecular species-hetero atom or an atomic group-purine ring, and is preferably represented by the general formula ( It is represented by I).
- one X— (CH 2) 1Y— moiety is a phosphorus that binds a purine ring to a released molecular species
- the linker portion is not particularly limited as long as it contains a heteroatom capable of decomposing guanine and can fix a released molecular species, but a preferred linker portion is the general formula (I ).
- X and Y are independently the same or different heteroatoms, and examples thereof include — ⁇ , —NH—, —N (alkyl) —, and —S—.
- alkyl group for —N (alkyl) — a linear or branched alkyl group having 110, preferably 115 carbon atoms
- an alkyl group such as a methyl group, an ethyl group and an n-propyl group can be mentioned.
- n is a force S representing an integer of 1 to 10, preferably 115, and one (CH) 1 is not necessarily a linear alkylene.
- alkylene group may be an alkylene group in which one or more methylene groups have been substituted with a hetero atom such as an oxygen atom or a nitrogen atom.
- Examples of the portion of 1 X— (CH 2) 1 Y— in the general formula (I) include the aforementioned NH— (C
- the R group in the general formula (I) represents a portion of a molecular species released by oxidation, and may be any group as long as it is released and can exhibit the function of the molecular species.
- Molecular species capable of expressing such a function are referred to herein as “functional units”.
- Such “functional units” include units that emit fluorescence, binding molecules such as avidin, reporter units that function as reporters for antigens and antibodies, and the regulation of biological functions in vivo, such as drugs and antibodies. Biofunctional molecules.
- the oligonucleotide used hybridizes to a specific gene, so that the oligonucleotide is localized in cells expressing a specific mRNA or the like.
- the drug is selectively released to the site by the oxidizing agent or light irradiation, and it becomes possible to obtain a site-selective DDS preparation.
- R 1 R 2 in the general formula (I) represents a linking group in the sugar moiety of the nucleoside
- R 2 may be a phosphate-bonding group for forming a force nucleotide, each being a hydrogen atom, or may be a protecting group or a phosphoramidide group used as an intermediate therefor.
- the compound represented by the general formula (I) of the present invention may be an oligonucleotide.
- the oligonucleotide contains a modified guanine derivative having a released molecular species as described above. It can be said that it is an oligonucleotide.
- Such an oligonucleotide of the present invention has at least one modified guanine derivative having a released molecular species, and may have two or more as needed. .
- R 2 in the general formula (I) represents various nucleotides. Become. Such nucleotides may have one or more bases.
- Such an oligonucleotide of the present invention may be very long, and there is no particular limitation on the length, but an oligonucleotide composed of 10 to 100 bases or 10 to 50 bases is preferred.
- the oligonucleotide of the present invention does not require a special electron donating group, but at least
- Oligonucleotides in which one base is a base that functions as an electron donating group are preferred.
- the modified guanine of the present invention can be decomposed by moving a long-range hole, so that two oligonucleotides containing at least one basic force electron-donating group in a complementary strand are used.
- Stranded oligonucleotides can also be mentioned as preferred oligonucleotides of the present invention.
- the present invention also provides a method for oxidizing the above-described oligonucleotide of the present invention to release the R group in the nucleotide represented by the general formula (I).
- FIG. 9 shows an outline of the release of the R group moiety of the present invention.
- a functional unit is bonded to the X part, and a hole is generated by the emission of one electron, which moves over a long range and is transmitted to the X part, and the functional unit of the X part is released from the oligonucleotide This is a schematic representation of what is done.
- FIG. 10 schematically shows a state in which a dye molecule is released as a functional unit from an oligonucleotide in the method of the present invention.
- Oxidation in this method of the present invention may be a relatively mild oxidation, such as a method by donating one electron, an oxidation by light irradiation, and an oxidation by iridium (IV) or Os (III).
- a relatively mild oxidation such as a method by donating one electron, an oxidation by light irradiation, and an oxidation by iridium (IV) or Os (III).
- nucleoside of the present invention after incorporation into an oligonucleotide, introduction of a functional unit by the formation of an amide-ester bond, and decomposition of the oligonucleotide by a mild oxidation reaction including light irradiation facilitates release of the functional unit. It is. Therefore, various functional units can be introduced irrespective of nucleic acid synthesis conditions, and the functional unit can be cut off from the oligonucleotide at a desired stage. After performing fluorescence measurements such as in situ hybridization, remove the fluorescent sites and release the drug at the target sequence. Exposure and decomposition of used labeled oligonucleotides are expected.
- Oxidation methods for releasing functional units include photo-oxidation using dyes such as riboflavin, oxidation with metal oxidants such as ( ⁇ ) ⁇ ⁇ 3 (111), and enzyme oxidation with horseradish peroxidase. .
- FIG. 1 shows the results of HPLC of degradation products of single-stranded oligonucleotides (ODN) of the present invention obtained by irradiation with light.
- FIG. 1 (a) shows the HPLC of a single-stranded oligonucleotide (ODN) as a raw material
- FIG. 1 (b) shows the result of HPLC of a decomposition product by light irradiation.
- FIG. 1 (c) shows the results of HPLC of the decomposition products of oxidation by iridium.
- FIG. 2 shows the results of MALDI-TOF of a decomposition product of the single-stranded oligonucleotide (ODN) of the present invention obtained by irradiation with light.
- the peak at 2370.61 in FIG. 2 is the peak of the starting oligonucleotide used as the internal standard.
- the peak at 1967.68 indicates the 5'-side decomposition product (8), and the peak at 1870.11 indicates the 3'-side decomposition product (9).
- FIG. 3 shows the results of LC-ESI / MSZMS analysis of a single-stranded oligonucleotide (ODN) of the present invention when irradiated with light.
- the upper part of Fig. 3 shows the eluate containing MS207, the middle part shows the fragmentation of MS207, and the lower part shows the liquid chromatography using an Intac C-18 column (2. OX 50mm). This shows the elution pattern of.
- FIG. 4 shows an outline of an oligonucleotide containing TAMRA- eda G of the present invention and an outline of a complementary strand thereof.
- FIG. 5 shows the fluorescence intensities obtained by irradiating ODNl / ODN2 (T) and ODNl / ODN2 (U *), which are double-stranded DNAs of the present invention, with 312 nm light, respectively (Fig. 5). (A)) and the degradation rate of the oligonucleotide (FIG. 5 (B)).
- the black circles indicate the case of ODN 1 / ODN2 (U *)
- the black squares (country) indicate the case of ODN1 / ODN2 (T).
- FIG. 5 indicates the fluorescence intensity (au), and the horizontal axis indicates the time (minutes) from light irradiation.
- the vertical axis of (B) in FIG. 5 indicates the decomposition rate (%), and the horizontal axis indicates the time (minutes) from light irradiation.
- FIG. 6 shows changes in fluorescence intensity as a result of irradiating ODN1 / ODN2 (U *), a double-stranded DNA of the present invention, with light at 312 nm.
- the vertical axis in FIG. 6 shows the fluorescence intensity (au), and the horizontal axis shows the wavelength (nm).
- Fig. 7 shows the results of PAGE analysis of the degradation products when ODN1 / ODN2 (U *), which is the double-stranded DNA of the present invention, was irradiated with light at 312nm.
- X in FIG. 7 indicates TAMRA- eda G.
- lane 1 shows the G + A sequence by the Maxam-Gilbert method
- lane 2 shows the full-length ODN1
- lane 3 shows the one immediately after light irradiation
- lane 4 shows the one after light irradiation for 30 minutes.
- Lane 5 shows the results for 60 minutes of light irradiation.
- FIG. 8 shows that the double-stranded DNA of the present invention, ODNl / ODN2 (T) (left side in FIG. 8) and ODNl / ODN2 (U *) (right side in FIG. It is a photograph replaced with a drawing showing the result when the fluorescence as a result of light irradiation is visually observed.
- FIG. 9 schematically shows the release of a functional unit from an oligonucleotide in the method of the present invention.
- FIG. 10 schematically shows a state in which a dye molecule is released as a functional unit from an oligonucleotide in the method of the present invention.
- Ethylenediamine (8-bromo-5, - ⁇ - (4,4, -dimethoxytrityl) -1 2'-deoxyguanosine (diol (1)) solution in lOOmU (2.Og, 30 .8 mmol) was stirred under reflux for 7 hours at 130 ° C. After concentration and drying, a crude product (2) was obtained as a brown oil.
- Example 2 The compound (2) obtained in Example 1 was stirred at 0 ° C for 2 hours in 50 mL of methanol in the presence of 10 mL of ethyl trifluoroacetate and 25 mL of triethylamine. After concentration and drying, the process proceeded to the next step.
- Example 3 To a solution of the compound (4) obtained in Example 3 (70 mg, 89.9 ⁇ 1) was added 2-cyanoethyl. A solution of tetraisopropyldiphosphoramidite (31 / iL, 98.9 ⁇ 1) and tetrazole (7 mg, 98.9 ⁇ 1) in acetonitrile (900 / iL) was added, and the mixture was stirred at room temperature for 2 hours. After filtering out the precipitated salt (I-Daniyo (5)), the filtrate was used for the next step as it was.
- acetonitrile 900 / iL
- oligodeoxyribonucleotides were synthesized by the conventional phosphoramidite method.
- the oligodeoxyribonutretide was subjected to reversed-phase high-performance liquid chromatography [5_ODS_H column (10 XI 50 mm), and elution was performed with acetate nitrile containing 0.1 M triethylammonium acetate (TEAA) ( ⁇ 7.0). (5%-> 20% / 30 min) at a flow rate of 3. OmL / min. ].
- TEAA triethylammonium acetate
- oligonucleotide (6) obtained in Example 5 was combined with 1 mg of a succinimidyl ester of a target functional molecule (for example, succinimidyl benzoate) in dimethyl sulfone.
- Functionalized oligonucleotide (7) was obtained by incubating 5 times 16 hours in 500 ⁇ L of 50 mM phosphate buffer ( ⁇ 70) to which 50 ⁇ L of a solution dissolved in 1 mL of hydroxide was added.
- a target functional molecule for example, succinimidyl benzoate
- This single-stranded oligonucleotide (ODN)
- 366 nm light was irradiated by a transilluminator to a 50 mM strength sodium codylate buffer ( ⁇ 7.0) containing an oligonucleotide corresponding to a base concentration of ImM and 50 ⁇ ⁇ of the one-electron oxidant riboflavin. About 90% was decomposed by irradiation for 1 minute, and almost all was decomposed by irradiation for 5 minutes. Analysis by decomposing to nucleoside units by enzymatic decomposition revealed that only the modified nucleoside was degraded and disappeared.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04771129A EP1652852B1 (en) | 2003-08-08 | 2004-08-02 | Nucleoside capable of releasing functional unit through oxidation and process for producing oligonucleotide containing the same |
US10/567,364 US7563886B2 (en) | 2003-08-08 | 2004-08-02 | Nucleoside releasing functional unit through oxidation and process for producing oligonucleotide containing thereof |
DE602004032032T DE602004032032D1 (de) | 2003-08-08 | 2004-08-02 | Nukleosid, das dazu in der lage ist, eine funktionelle einheit durch oxidation freizusetzen, und verfahren zur herstellung eines dieses enthaltenden oligonukleotids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-289972 | 2003-08-08 | ||
JP2003289972A JP3929949B2 (ja) | 2003-08-08 | 2003-08-08 | 酸化により機能性ユニットを放出するヌクレオシドおよびそれを含むオリゴヌクレオチドの製造法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005014610A1 true WO2005014610A1 (ja) | 2005-02-17 |
Family
ID=34131571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/011039 WO2005014610A1 (ja) | 2003-08-08 | 2004-08-02 | 酸化により機能性ユニットを放出するヌクレオシドおよびそれを含むオリゴヌクレオチドの製造法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7563886B2 (ja) |
EP (1) | EP1652852B1 (ja) |
JP (1) | JP3929949B2 (ja) |
DE (1) | DE602004032032D1 (ja) |
WO (1) | WO2005014610A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61112077A (ja) * | 1984-09-20 | 1986-05-30 | ピエレル・ソチエタ・ペル・アチオニ | 8−置換されたヌクレオシド及びプリン誘導体 |
JPH01500353A (ja) * | 1986-07-22 | 1989-02-09 | アンステイテユ・パストウール | 2′‐デオキシアデノシン誘導体を含む核酸検出用プローブ |
JP2001270896A (ja) * | 1991-02-08 | 2001-10-02 | Pro Neuron Inc | 造血改善のためのオキシプリンヌクレオシド、およびそれらの同族体、ならびにそのアシル誘導体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1202321B (it) * | 1985-06-06 | 1989-02-02 | Uni Degli Studi Di Parmo | Nucleotidi ciclici fluorescenti biologicamente attivi |
US4910300A (en) * | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
WO2003042658A2 (en) * | 2001-11-09 | 2003-05-22 | Aclara Biosciences, Inc. | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
-
2003
- 2003-08-08 JP JP2003289972A patent/JP3929949B2/ja not_active Expired - Fee Related
-
2004
- 2004-08-02 WO PCT/JP2004/011039 patent/WO2005014610A1/ja active Application Filing
- 2004-08-02 US US10/567,364 patent/US7563886B2/en not_active Expired - Fee Related
- 2004-08-02 EP EP04771129A patent/EP1652852B1/en not_active Expired - Lifetime
- 2004-08-02 DE DE602004032032T patent/DE602004032032D1/de not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61112077A (ja) * | 1984-09-20 | 1986-05-30 | ピエレル・ソチエタ・ペル・アチオニ | 8−置換されたヌクレオシド及びプリン誘導体 |
JPH01500353A (ja) * | 1986-07-22 | 1989-02-09 | アンステイテユ・パストウール | 2′‐デオキシアデノシン誘導体を含む核酸検出用プローブ |
JP2001270896A (ja) * | 1991-02-08 | 2001-10-02 | Pro Neuron Inc | 造血改善のためのオキシプリンヌクレオシド、およびそれらの同族体、ならびにそのアシル誘導体 |
Non-Patent Citations (4)
Title |
---|
MA Z. ET AL.: "Nucleic acid-triggered catalytic drug release", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 21, 2000, pages 11159 - 11163, XP002903500 * |
OKAMOTO A. ET AL.: "Phototriggered drug release from functionalized oligonucleotides by a molecular beacon strategy", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 42, no. 22, 2003, pages 2502 - 2504, XP002903499 * |
See also references of EP1652852A4 * |
WU X. ET AL.: "Synthesis and biological activity of a bivalent nucleotide inhibitor of ribonucleotide reductase.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 20, 2000, pages 2387 - 2389, XP004224224 * |
Also Published As
Publication number | Publication date |
---|---|
US20070270582A1 (en) | 2007-11-22 |
JP2005058039A (ja) | 2005-03-10 |
EP1652852A4 (en) | 2009-08-12 |
EP1652852B1 (en) | 2011-03-30 |
EP1652852A1 (en) | 2006-05-03 |
US7563886B2 (en) | 2009-07-21 |
JP3929949B2 (ja) | 2007-06-13 |
DE602004032032D1 (de) | 2011-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0135587B2 (en) | Defined sequence single strand oligonucleotides incorporating reporter groups, process for the chemical synthesis thereof, and nucleosides useful in such synthesis | |
EP1877415B1 (en) | New labelling strategies for the sensitive detection of analytes | |
ES2369299T3 (es) | Química de click para la producción de moléculas informadoras. | |
US20040192918A1 (en) | Novel nucleoside analogs and oligonucleotide derivatives containing these analogs | |
US20030144231A1 (en) | Oligonucleotide analogues | |
JPH07300494A (ja) | 新規なデオキシリボヌクレオシドホスホルアミダイト及びオリゴヌクレオチドを製造するためのそれらの使用 | |
US7960543B2 (en) | Nucleoside or nucleotide derivative and use thereof | |
JPS60500717A (ja) | リポ−タ−グル−プを含んでいる一定配列の1本鎖オリゴヌクレオチド、およびその化学的合成法 | |
JP5598784B2 (ja) | 標的核酸の分析方法、キットおよび分析機器 | |
EP0688784A2 (de) | Neue 3'-Modifizierte Oligonucleotid-Derivate | |
KR20220163359A (ko) | 신규 mRNA 5'-말단 캡 유사체, 이를 혼입한 RNA 분자, 이의 용도 및 RNA 분자 또는 펩티드의 합성 방법 | |
JP4712814B2 (ja) | 特定の塩基配列の標的核酸類を検出する方法、及び検出のための核酸類セット | |
JP3753942B2 (ja) | 5−ピリミジン含有核酸、それを用いた可逆的連結方法 | |
DE60123056T2 (de) | Basenanaloge | |
WO2005014610A1 (ja) | 酸化により機能性ユニットを放出するヌクレオシドおよびそれを含むオリゴヌクレオチドの製造法 | |
ES2352509T3 (es) | Nuevas estrategias de marcaje para la detección sensible de analitos. | |
US7205396B2 (en) | Benzodeazaadenine derivative base and electronic material containing the same | |
JPH05501418A (ja) | オリゴヌクレオチドの官能化方法 | |
KR20210116216A (ko) | 뉴클레오티드의 선택적 변형 방법 | |
Singh et al. | Synthesis and fluorescence studies of fluorescently labelled phosphoramidites: synthons for multiple labelled oligonucleotides | |
JP2004166522A (ja) | ポリヌクレオチド誘導体及びその利用 | |
DE4420737A1 (de) | Neue 3'-Modifizierte Oligonucleotid-Derivate | |
Hu | Kore et a1. | |
WO2007105623A1 (ja) | オリゴヌクレオチド固定化固相担体 | |
DE4424263A1 (de) | Neue 3'-Modifizierte Oligonucleotid-Derivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10567364 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004771129 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004771129 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10567364 Country of ref document: US |